A Phase I Study of TheraCIM-hR3 (YMB1000) [nizotuzumab] in Patients With Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 20 Apr 2007
At a glance
- Drugs Nimotuzumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors YM BioSciences
- 20 Apr 2007 Status changed from recruiting to completed.
- 23 Oct 2006 New trial record.